You searched for "ischaemia"
Tackling diabetic retinopathy globally through the VISION 2020 LINKS Diabetic Retinopathy Network
1 February 2017
| Nick Astbury, Philip Burgess, Allen Foster (Prof), Denise Mabey, Marcia Zondervan
|
EYE - Cataract, EYE - Cornea, EYE - Glaucoma, EYE - Imaging, EYE - Neuro-ophthalmology, EYE - Oculoplastic, EYE - Oncology, EYE - Orbit, EYE - Paediatrics, EYE - Pathology, EYE - Refractive, EYE - Strabismus, EYE - Vitreo-Retinal, EYE - General
It is abundantly clear that the burden of diabetes is rapidly increasing, as there are now 415 million adults with diabetes in the world, with a projected rise to 642 million by 2040 [1]. This equates to 1 in 10...
Ciliary body granuloma masquerading as a melanoma
3 February 2023
| Boon Lin Teh, Paul Cauchi, Lucia Kuffová
|
EYE - General
Introduction Sarcoidosis is a multisystem granulomatous inflammatory condition which predominantly affects the pulmonary system and intrathoracic lymph nodes, followed by ocular involvement [1]. We present an interesting patient who developed acute anterior uveitis and subsequent ciliary body granuloma clinically mimicking...
Don’t ignore the black lesion! It might be mucormycosis
1 June 2017
| Tina Parmar
|
EYE - Cornea
Keeping mucormycosis infection in the foreground of your differential diagnosis, especially in those more vulnerable patients, will help save their lives if recognised and managed appropriately. Mucormycosis is a fulminant infection caused by the fungi of the family Mucoraceae. It...
The eye without tears
1 June 2016
| Hector Bryson Chawla
|
EYE - General
The Art is long and Life is short. So goes the dispiriting tag in Latin and flung from day one and at regular intervals thereafter at idle medical students who, inevitably brainwashed, come by graduation to believe that the only...
Regulatory drug evaluations and expedited review initiatives: EU and US perspectives
1 April 2016
| Rod McNeil
|
EYE - General
The European Medicines Agency (EMA) and United States Food and Drug Administration (FDA) each conduct independent assessments of benefit-risk profile when evaluating applications to market new or modified medicines, and their respective decision-making is guided by distinct legislation, procedures and...
COVID-19: Pete’s Bogus Journey
6 April 2021
| Peter Cackett
|
EYE - General
The author shares his personal experience of contracting coronavirus. I managed to body swerve COVID-19 for nine months. The Pfizer vaccine was being rolled out in my trust. I had my first inoculation booked in three weeks. I had survived...
Childhood glaucoma
When a child is given a diagnosis of glaucoma, the impact upon that child and their family is enormous; equivalent to the diagnosis of a cancer [14]. This article outlines the knowledge, techniques and approaches that offer solutions to the...Redefining healthcare through the eyes
4 February 2025
| Ashkan Eliasy
|
EYE - Cornea, EYE - Imaging, EYE - Neuro-ophthalmology, EYE - General
The future of healthcare is being shaped by innovation in eyecare and in particular a field known as oculomics. This discipline leverages ocular biomarkers to provide insights into various health conditions, including cardiovascular diseases and psychological or neurological disorders [1]....
